FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3132602007> ?p ?o ?g. }

• W3132602007 endingPage "44" @default.
• W3132602007 startingPage "PS10" @default.
• W3132602007 abstract "Abstract Background: Trastuzumab has been used for HER2 positive breast cancer treatment for more than 20 years. The ratio of HER2 overexpression in breast cancer patients is about 20%. In this study, we aim to evaluate the prognosis of HER2 positive breast cancer patients with long term received trastuzumab and examined the predictors of complete response. Method: In this study, we included the patients with HER2 positive metastatic breast cancer received long-term trastuzumab. Demographic, clinical, pathological, and treatment data of the patients retrospectively recorded. Response rates of trastuzumab-based treatment evaluated by RECIST. The prognosis of the patients and predictors of complete response assessed with Kaplan-Meier analysis and logistic regression analysis, respectively. Also, the prognosis of the patients whose trastuzumab-based treatment was terminated was evaluated. Results: Median follow-up was 123.3 months (range, 32.2-330.3). Eighty patients included the study, and the median age of the patients was 43 (22-68). The patients received trastuzumab-based treatment with a median of 62 months (range, 12-191). The number of de-novo metastatic patients was 27 (33.8%). All patients had a pathological HER2 overexpressed tumor that scored 3+ (71.3%) by ımmunohistochemistry (IHC) or scored 2+ (28.7%) by IHC confirmed with FISH. In all patients, five-, ten-, and, fifteen – years overall survival were 96.1%, 86.8%, and 60.5%, respectively. A complete response was detected at 60 (75%) of the patients. The median time to complete response was 14.4 months (range, 2.4-47.8). In logistic-regression analysis: age at diagnosis (p=0.543), menopausal status (p=0.074), bisphosphonates treatment (p=0.682), palliative radiotherapy (p=0.935), and de-novo metastatic disease (p=0.405) were not statistically significant predictors for complete response. However, the number of metastatic sites (p=0.016), and the use of endocrine therapy (p=0.019) with trastuzumab were statistically significant. During the study period, trastuzumab-based treatment of twelve patients was terminated, four (33.3%) patients continue to receive aromatase inhibitör, and eight (66.7%) patients received no treatment. After termination of trastuzumab, at a median follow-up 44.7 months (range, 11.6-66.6), recurrence was not detected in the patients. Conclusions: In this study, we found that trastuzumab-based therapy can provide full recovery of HER2 positive metastatic breast cancer. For the patients with a long-term complete response, discontinuation of trastuzumab-based treatment should be considered. Also, hormone-positive patients should continue to receive aromatase inhibitör. The use of endocrine therapy with trastuzumab and the number of metastatic sites are predictors of the complete response Citation Format: Izzet Dogan, Esra Aydın, Nijat Khanmammadov, Adnan Aydıner, Pınar Saip. Termination of trastuzumab-based treatment after complete response in HER2-positive metastatic breast cancer [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS10-44." @default.
• W3132602007 created "2021-03-01" @default.
• W3132602007 creator A5008743491 @default.
• W3132602007 creator A5012785018 @default.
• W3132602007 creator A5015315660 @default.
• W3132602007 creator A5045255203 @default.
• W3132602007 creator A5077708447 @default.
• W3132602007 date "2021-02-15" @default.
• W3132602007 modified "2023-09-30" @default.
• W3132602007 title "Abstract PS10-44: Termination of trastuzumab-based treatment after complete response in HER2-positive metastatic breast cancer" @default.
• W3132602007 doi "https://doi.org/10.1158/1538-7445.sabcs20-ps10-44" @default.
• W3132602007 hasPublicationYear "2021" @default.
• W3132602007 type Work @default.
• W3132602007 sameAs 3132602007 @default.
• W3132602007 citedByCount "0" @default.
• W3132602007 crossrefType "journal-article" @default.
• W3132602007 hasAuthorship W3132602007A5008743491 @default.
• W3132602007 hasAuthorship W3132602007A5012785018 @default.
• W3132602007 hasAuthorship W3132602007A5015315660 @default.
• W3132602007 hasAuthorship W3132602007A5045255203 @default.
• W3132602007 hasAuthorship W3132602007A5077708447 @default.
• W3132602007 hasConcept C121608353 @default.
• W3132602007 hasConcept C126322002 @default.
• W3132602007 hasConcept C143998085 @default.
• W3132602007 hasConcept C151956035 @default.
• W3132602007 hasConcept C207886595 @default.
• W3132602007 hasConcept C2775930923 @default.
• W3132602007 hasConcept C2779786085 @default.
• W3132602007 hasConcept C530470458 @default.
• W3132602007 hasConcept C71924100 @default.
• W3132602007 hasConcept C90924648 @default.
• W3132602007 hasConceptScore W3132602007C121608353 @default.
• W3132602007 hasConceptScore W3132602007C126322002 @default.
• W3132602007 hasConceptScore W3132602007C143998085 @default.
• W3132602007 hasConceptScore W3132602007C151956035 @default.
• W3132602007 hasConceptScore W3132602007C207886595 @default.
• W3132602007 hasConceptScore W3132602007C2775930923 @default.
• W3132602007 hasConceptScore W3132602007C2779786085 @default.
• W3132602007 hasConceptScore W3132602007C530470458 @default.
• W3132602007 hasConceptScore W3132602007C71924100 @default.
• W3132602007 hasConceptScore W3132602007C90924648 @default.
• W3132602007 hasIssue "4_Supplement" @default.
• W3132602007 hasLocation W31326020071 @default.
• W3132602007 hasOpenAccess W3132602007 @default.
• W3132602007 hasPrimaryLocation W31326020071 @default.
• W3132602007 hasRelatedWork W1722328147 @default.
• W3132602007 hasRelatedWork W188069312 @default.
• W3132602007 hasRelatedWork W2001196910 @default.
• W3132602007 hasRelatedWork W2130521606 @default.
• W3132602007 hasRelatedWork W2158916914 @default.
• W3132602007 hasRelatedWork W2934076975 @default.
• W3132602007 hasRelatedWork W3112926233 @default.
• W3132602007 hasRelatedWork W4253790588 @default.
• W3132602007 hasRelatedWork W4383618614 @default.
• W3132602007 hasRelatedWork W2342209702 @default.
• W3132602007 hasVolume "81" @default.
• W3132602007 isParatext "false" @default.
• W3132602007 isRetracted "false" @default.
• W3132602007 magId "3132602007" @default.
• W3132602007 workType "article" @default.